Behandlung von Non-Hodgkin-Lymphom in Israel — erhalten Sie 3 personalisierte Klinikempfehlungen

Israel offers advanced therapies like in-house CAR T-cell therapy and bispecific T-cell engagers (BiTEs) for Non-Hodgkin's lymphoma. JCI-accredited centers like Sheba Medical Center manufacture custom immunotherapy locally. This reduces wait times to 10 days. Precision diagnostics and bone marrow transplants provide high-efficacy care for relapsed cases.

• CAR-T therapy: Locally engineered T-cells target specialized antigens to destroy treatment-resistant lymphoma cells.
• Bispecific antibodies: Advanced agents like BiTEs bridge immune cells directly to tumors for destruction.
• Genomic profiling: FoundationOne CDx sequencing identifies mutations to match patients with targeted biological drugs.
• Advanced transplantation: Sterile HEPA-isolation units support autologous and allogeneic bone marrow transplants using donor registries.

Bookimed Expert Insight: Israeli oncology centers like Sheba Medical Center capitalize on local production to bypass logistics delays. While commercial CAR-T in the US often takes weeks, Israeli in-house manufacturing can prepare cells in just 10 days. For patients with aggressive DLBCL, this two-week time saving can be the difference in maintaining treatment eligibility.

Patient Consensus: Patients note that access to clinical trials for bispecific antibodies moved much faster than US waitlists. Many emphasize the importance of packing for a 4-to-8 week stay and arranging tele-oncology for post-treatment follow-up.

Israel is a global leader in lymphoma care. Major centers like Sheba Medical Center and Sourasky Medical Center specialize in CAR-T cell therapy. These facilities combine advanced molecular diagnostics with bone marrow transplantation. Most primary hospitals maintain JCI accreditation for international safety and quality.

• Sheba Medical Center: Ranked among the best globally. It offers in-house CAR-T cell manufacturing.
• Sourasky (Ichilov): Specializes in aggressive lymphomas. It provides genetic sequencing for targeted therapies.
• Hadassah Medical Center: Known for high success rates in allogeneic bone marrow transplants.
• Rambam Medical Center: Features a dedicated hematology emergency room for immunocompromised patients.

Bookimed Expert Insight: Israeli hospitals offer a distinct advantage for pediatric cases. A specialized package at Sheba Medical Center covers 30 days of hospitalization. This extended stay is crucial for monitoring heavy treatments like bone marrow transplants. Prof. Dr. Amos Toren even includes consultations with cardiologists and immunologists to manage treatment side effects.

Patient Consensus: Patients note that larger centers like Hadassah offer targeted therapies with minimal side effects. Many emphasize that while larger hospitals provide incredible care, bureaucracy can sometimes delay treatment starts for international visitors.

Israeli medical centers report response rates up to 95% for advanced lymphoma treatments. Success for Hodgkin lymphoma involves chemo-biologic regimens with 83% early response. Leading facilities like Sheba Medical Center achieve 70% to 88% response rates using CAR T-cell therapy for refractory Non-Hodgkin cases.

• Hodgkin response: Combined chemo-biologic protocols reach a 95% complete response rate.
• CAR-T outcomes: Follicular lymphoma patients show an 88% complete response at Sheba.
• Pediatric success: Response rates for children reach 70% to 90% at specialized units.
• Bone marrow: Transplant packages often integrate CAR-T platforms for high-risk pediatric cases.

Bookimed Expert Insight: While Sheba Medical Center serves over 1.9 million patients annually, the real advantage lies in scale-driven research. Specialists like Dr. Abraham Avigdor and Dr. Elad Jacoby provide patients access to local CAR-T production. This internal manufacturing at Hadassah and Sheba allows for response rates exceeding 90% in specific trials. This capability is often faster and more flexible than centers relying on commercial pharmaceutical shipments.

Patient Consensus: Patients emphasize the need to clarify the difference between initial response and long-term remission. Many advise preparing for potential ICU stays due to side effects like cytokine-release storms during immunotherapy.

Complex lymphoma treatment in Israel typically requires a stay of 4 to 8 weeks for intensive phases. Bone marrow transplants usually involve 30 days of hospitalization. Advanced CAR T-cell therapy requires approximately 4 to 6 weeks. Standard chemotherapy cycles may extend the total duration to 4 or 6 months.

• Diagnostic phase: Initial assessments and personalized protocol design usually take 3 to 5 working days.
• Hospitalization period: Bone marrow transplant packages at Sheba Medical Center include a 30-day inpatient stay.
• CAR-T timeline: Cell manufacturing takes 10–14 days followed by 21 days of inpatient monitoring.
• Recovery monitoring: Patients stay near the facility for several weeks post-discharge for frequent check-ups.

Bookimed Expert Insight: Data shows Sheba Medical Center packages bundle a full 30-day hospital stay for transplants. This is significant because many clinics elsewhere charge daily for inpatient care. Choosing a bundled stay helps manage budgets while ensuring 24-hour access to specialized nurse services.

Patient Consensus: Patients note it is smart to plan for 8–12 weeks total to account for potential recovery delays. They suggest booking flexible accommodation like an Airbnb near the clinic instead of tight return flights.